admin

Miami International Holdings Reports Trading Results for December and Full-Year 2024; MIAX Exchange Group Sets Multiple Volume and Market Share Records in Options and Equities Markets Middle East - English USA - English

Miami International Holdings Reports Trading Results for December and Full-Year 2024; MIAX Exchange Group Sets Multiple Volume and Market Share Records in Options and Equities Markets Middle East – English USA – English

MIAMI AND PRINCETON, N.J., Jan. 8, 2025 /PRNewswire/ — Miami International Holdings, Inc. (MIH), a technology-driven leader in building and operating regulated financial markets across multiple asset classes, today reported December and full-year 2024 trading results for its U.S. exchange subsidiaries – MIAX®, MIAX Pearl®, MIAX Emerald® and MIAX SapphireTM (collectively, the MIAX Exchange Group),…

Read More
a credit card secured by your car

a credit card secured by your car

For high-earning borrowers with prime credit, there’s no shortage of lenders willing to offer easy loans or credit cards that come with perks like cash back and travel rewards. For everyone else, lending options can be limited—and often predatory. That’s why the fintech startup Yendo is trying to make borrowing more accessible by offering loans…

Read More
ACCESSWIRE

Future Fuels Inc. Announces Changes to its Board of Directors & Grants Stock Options

VANCOUVER, BC / ACCESSWIRE / January 7, 2025 / Future Fuels Inc. (the “Company” or “Future Fuels”) (TSXV:FTUR)(FWB:S0J) is pleased to announce the appointment Bernd Christmas and Mark Riccio to its board of directors. Mr. Christmas is a highly esteemed legal professional and advocate for First Nations across Canada, recognized for his extensive experience and…

Read More
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics, Inc. WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris’ Board of Directors (the Committee) granted nonstatutory stock options to purchase…

Read More
Back To Top